

*Appendix 4: List of questions with no consensus in the first Delphi round (left column) and reformulated questions for the second Delphi round (right column)*

Delphi round 1 questions	Survey results	Delphi round 2 questions	Survey results
<b>PAIN</b>			
What scale is most appropriate to evaluate the presence of pain in a non-verbal adult with ID? - EDAAP - GED-DI - Other - Does not know	7 (39%) 5 (28%) 3 (17%) 3 (17%)	Do you think that the choice of the EDAAP scale to assess the presence of pain in a non-verbal adult with ID is relevant? - Yes - No	16 (89%) 2 (11%)
What is the appropriate number of caregivers to rate the intensity of pain in a non-verbal adult with ID? - 1 - 2 - 3 - Does not know	6 (33%) 8 (44%) 2 (11%) 2 (11%)	Do you think that the rating of pain intensity for non-verbal adults with ID by two caregivers seems relevant? - Yes - No	14 (78%) 4 (22%)
Do you think it is relevant to systematically co-prescribe a proton pump inhibitor (PPI) with an NSAID for patients over 60 years of age? - Yes - No - Does not know	6 (33%) 8 (44%) 4 (22%)	Do you think it is relevant to systematically co-prescribe a proton pump inhibitor (PPI) with a NSAIDs for patients with at least two risk factors (age >65 years; history of peptic ulcer; concomitant treatment with anticoagulants, antiaggregants or glucocorticoids) as recommended for the general population? - Yes - No	15 (83%) 3 (17%)
Does the choice of tapentadol seem relevant to you if the patient is taking a CYP2D6 inhibitor or has a risk of serotonin syndrome for moderate pain? - Yes - No - Does not know	5 (28%) 6 (33%) 7 (39%)	Does the choice of tapentadol seem relevant to you if the patient is taking a CYP2D6 inhibitor or has a risk of serotonin syndrome for moderate pain? - Yes - No	18 (100%) 0 (0%)
<b>SLEEP</b>			
Do you think the dose of melatonin should be increased if there is no response? If so, up to what dose? - 2 mg - 4 mg - 6 mg - Other - Does not know	2 (11%) 4 (22%) 7 (39%) 1 (6%) 4 (22%)	Do you think it is relevant to say that the melatonin dose can be increased up to 6mg? - Yes - No	16 (89%) 2 (11%)

Do you think that the choice of hydroxyzine in case of transient insomnia is relevant? - Yes - No - Does not know	9 (50%) 6 (33%) 3 (17%)	➔ Zolpidem and oxazepam were the only treatments for which a consensus was found between the experts during the first Delphi round so hydroxyzine and trazodone were removed from the tool	
Do you think it is necessary to add trazodone as a treatment for transient insomnia? - Yes - No - Does not know	6 (33%) 8 (44%) 4 (22%)	Do you think that the choice to keep zolpidem and oxazepam only as a treatment for transient insomnia is relevant? - Yes - No	17 (94%) 1 (6%)
<b>CHALLENGING BEHAVIOURS</b>			
Do you think that the combination of risperidone and lorazepam is relevant in the case of a challenging behaviour requiring sedation? - Yes - No - Does not know	9 (50%) 6 (33%) 3 (17%)	Do you think that the choices of risperidone combined with lorazepam, or olanzapine in the case of a challenging behaviour requiring sedation are relevant? - Yes - No	15 (83%) 3 (17%)
Do you think that the choice of olanzapine for a challenging behaviour requiring sedation is relevant? - Yes - No - Does not know	8 (44%) 5 (28%) 5 (28%)		
Do you think that the choice of valproate in second line in case of challenging behaviour is relevant? - Yes - No - Does not know	8 (44%) 5 (28%) 5 (28%)	Do you think that the choice of valproate in second line in case of challenging behaviour is relevant? - Yes - No	14 (78%) 4 (22%)
Do you agree with systematically stopping the psychotropic treatment prescribed for a challenging behaviour after 6 weeks? - Yes - No - Does not know	5 (28%) 7 (39%) 6 (33%)	Do you agree with systematically stopping the psychotropic treatment prescribed for a challenging behaviour after 6 weeks? - Yes - No	16 (89%) 2 (11%)
<b>DEPRESCRIPTION</b>			
Do you think that the threshold of 4 psychotropic drugs to assess the need for deprescription is relevant? - Yes - No - Does not know	10 (56%) 7 (39%) 1 (6%)	Do you think that the threshold of 3 psychotropic drugs to assess the need for deprescription is relevant? - Yes - No	12 (67%) 6 (33%)

<p>After how long do you think the efficacy of an antidepressant treatment should be reassessed?</p> <ul style="list-style-type: none"> <li>- 4 weeks</li> <li>- 6 weeks</li> <li>- 8 weeks</li> <li>- Other</li> <li>- Does not know</li> </ul>	<p>8 (44%) 6 (33%) 3 (17%) 0 (0%) 1 (6%)</p>	<p>Do you agree with reassessing the indication for an antidepressant treatment according to the guidelines in the general population, after a 4-week therapeutic trial?</p> <ul style="list-style-type: none"> <li>- Yes</li> <li>- No</li> </ul>	<p>15 (83%) 3 (17%)</p>
<p>After how long do you think the efficacy of an antipsychotic treatment should be reassessed?</p> <ul style="list-style-type: none"> <li>- 2 weeks</li> <li>- 4 weeks</li> <li>- 3 months</li> <li>- Other</li> <li>- Does not know</li> </ul>	<p>9 (50%) 7 (39%) 0 (0%) 0 (0%) 2 (11%)</p>	<p>Do you agree with reassessing the indication for an antipsychotic treatment according to the guidelines in the general population, after a 4-week therapeutic trial?</p> <ul style="list-style-type: none"> <li>- Yes</li> <li>- No</li> </ul>	<p>16 (89%) 2 (11%)</p>
<p>After how long do you think the efficacy of a stimulant treatment should be reassessed?</p> <ul style="list-style-type: none"> <li>- 2 weeks</li> <li>- 4 weeks</li> <li>- Other</li> <li>- Does not know</li> </ul>	<p>9 (50%) 4 (22%) 1 (6%) 4 (22%)</p>	<p>Do you agree with reassessing the indication for a stimulant treatment according to the guidelines in the general population, after a 6-week therapeutic trial?</p> <ul style="list-style-type: none"> <li>- Yes</li> <li>- No</li> </ul> <p>→ The duration was changed based on the guidelines</p>	<p>17 (94%) 1 (6%)</p>
<p>After how long do you think the efficacy of an analgesic treatment should be reassessed?</p> <ul style="list-style-type: none"> <li>- 2 weeks</li> <li>- 4 weeks</li> <li>- Other</li> <li>- Does not know</li> </ul>	<p>7 (39%) 2 (11%) 5 (28%) 4 (22%)</p>	<p>→ The item was removed from the tool because reassessment depends too much on the type of analgesic treatment.</p>	